Clinical Trial Site
Münster 48149
4 studies enrolling now · 11 studies all time
What they study most
Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Atypical Hemolytic-Uremic Syndrome, Familial Amyloid Polyneuropathies, Familial Transthyretin Cardiac Amyloidosis, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy, TTR-mediated Amyloidosis
Studies at this site
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy — Recruiting now
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
- Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program — Recruiting now
- Atypical Hemolytic-Uremic Syndrome (aHUS) Registry — Recruiting now
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
- HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) — Completed
- APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis — Completed
- Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis — Completed
- The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed
- The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed
- ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) — Completed